Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial.
Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
